Market closed
MAIA Biotechnology Inc./$MAIA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Ticker
$MAIA
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
13
Website
MAIA Metrics
BasicAdvanced
$46M
-
-$1.05
0.21
-
Price and volume
Market cap
$46M
Beta
0.21
52-week high
$2.09
52-week low
$1.40
Average daily volume
100K
Financial strength
Current ratio
2.651
Quick ratio
2.527
Interest coverage (TTM)
-297,494.91%
Management effectiveness
Return on assets (TTM)
-119.60%
Return on equity (TTM)
-1,131.02%
Valuation
Price to book
11.16
Price to tangible book (TTM)
11.16
Price to free cash flow (TTM)
-2.191
Growth
Earnings per share change (TTM)
-29.74%
3-year earnings per share growth (CAGR)
-23.81%
MAIA News
AllArticlesVideos
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
Business Wire·3 weeks ago
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
Business Wire·4 weeks ago
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MAIA Biotechnology Inc. stock?
MAIA Biotechnology Inc. (MAIA) has a market cap of $46M as of April 20, 2025.
What is the P/E ratio for MAIA Biotechnology Inc. stock?
The price to earnings (P/E) ratio for MAIA Biotechnology Inc. (MAIA) stock is 0 as of April 20, 2025.
Does MAIA Biotechnology Inc. stock pay dividends?
No, MAIA Biotechnology Inc. (MAIA) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next MAIA Biotechnology Inc. dividend payment date?
MAIA Biotechnology Inc. (MAIA) stock does not pay dividends to its shareholders.
What is the beta indicator for MAIA Biotechnology Inc.?
MAIA Biotechnology Inc. (MAIA) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.